Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Spinal muscular atrophy approval boosts antisense drugs. Nat Biotechnol 35, 99–100 (2017). https://doi.org/10.1038/nbt0217-99
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0217-99
- Springer Nature America, Inc.
This article is cited by
-
Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1
Gene Therapy (2022)
-
An Evidence‐Based, Community‐Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials
Journal of Genetic Counseling (2018)
-
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Genome Medicine (2017)
-
Biogen pays Forward in Tecfidera dispute
Nature Biotechnology (2017)
-
LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts
Scientific Reports (2017)